Strategic evidence
1 of 6
Primary Biological Systems
The lymphatic system governs immune function, metabolic waste clearance, fluid balance, and inflammation. It is the only one without a category leader.
LX
lymphexlymphatic intelligence platform
The Lymphatic Intelligence Platform.
Unlocking the last major biological system without a category leader.
Every major biological system has been commercialized through category-defining devices, drugs, and platforms. The lymphatic system — despite governing immune function, fluid balance, inflammation, and metabolic waste clearance — remains strategically unowned.
Investment SummaryConfidential 2026
Platform Scope3 ProductsOne evidence engine; one data asset.
White Space$59BCurrent annual revenue pools without a system owner.
Strategic LogicSystem FirstIncumbents treat symptoms; Lymphex addresses the underlying biology.
Exit LogicCategory AcquisitionPlatform, patent, and reference dataset over single-SKU monetization.
01 — The Problem
The Lymphatic System Is Invisible. That Is the Opportunity.
Lymphex is positioning around a structural omission in modern healthcare: one of the six primary biological systems remains largely non-commercialized, non-measured, and strategically fragmented across symptom-specific categories.
Strategic evidence
10M+
Americans with Lymphedema
The diagnosable population is just the surface. Subclinical lymphatic dysfunction affects orders of magnitude more people, entirely undetected.
Strategic evidence
$0
Annual Revenue — Consumer Lymphatic Category
No consumer brand. No platform device. No company whose primary business is lymphatic health. The category does not yet exist.
Strategic evidence
Age 40+
When Degradation Accelerates
Lymphatic function declines sharply after 40 — coinciding with the explosion in filler use, metabolic disease, sleep disorders, and neurodegenerative risk.
02 — Market Opportunity
$59 Billion in Annual Revenue. Zero Category Leaders.
The markets below are already sizable, growing, and actively commercialized. What is missing is a company that addresses the underlying lymphatic system rather than intervening symptom by symptom.
| Indication | Current Market (TTM) | CAGR | 2030 Projection | Lymphex Role |
|---|---|---|---|---|
| Lymphedema Treatment | $2.0B | 8.8% | $3.0B | Core device market |
| Lymphatic Drainage Equipment | $500M | 10.2% | $1.2B | LymphLens + LymphRelief |
| Gout Therapeutics | $3.0B | 7.4% | $4.7B | Patent indication |
| Restless Leg Syndrome | $730M | 5.2% | $940M | Patent indication |
| Erectile Dysfunction | $4.8B | 6.7% | $7.2B | Patent indication |
| Urinary Incontinence | $8.3B | 7.5% | $11.0B | Patent indication |
| Alzheimer’s / Glymphatic | $6.5B | 20%+ | $33.6B | Holy grail indication |
| Neurodegenerative (broader) | $15.0B | 8–12% | $25B+ | Platform play |
| Medical Aesthetics | $18.0B | 12% | $32B | B2B device channel |
| TOTAL | ~$59B | — | ~$118B | Lymphex owns the white space |
“Every major market above is being addressed symptom by symptom. Lymphex is the first company to address the underlying system.”
Strategic interpretation
The opportunity is not a single product category. It is a systems-level entry point into device, therapeutic, neurodegenerative, and aesthetic revenue pools currently commercialized through disconnected symptom pathways.
03 — The Platform
Three Products. One Evidence Engine. One Platform.
The platform is designed to move from mass adoption to intervention proof to strategic acquisition logic. Consumer engagement funds evidence generation; evidence supports premium device economics and licensing leverage.
Product 1
LymphLens
Free App
5-day smartphone photo assessment. Face, hands, feet, lower legs. AI generates a Lymphatic Drainage Score and personalized visual simulation. Aesthetic hook drives mass consumer adoption. Anonymized data builds world’s first lymphatic health database.
Clinical Paper #1 — Population Baseline
Product 2
LymphRelief
Consumer Product
Consumer lymphatic wellness product designed for repeat at-home use. The ergonomic S-curve form factor and tactile guidance create a simple daily ritual that complements the LymphLens assessment experience and supports broad direct-to-consumer adoption.
Consumer Engagement Layer
Product 3
LymphRestore
Class I Device
Class I FDA registered mechanical drainage device. Sinusoidal S-curve ergonomic form factor. Dual-lobe working surface with faceted crystal applicator. QR linkage connects the device to each user’s LymphLens profile and personalized drainage plan.
Clinical Paper #2 — Intervention Efficacy
04 — Data Flywheel
The Asset Is the Data. The Products Fund the Science.
The investment case rests on compounding evidence. Lymphex is not simply building products; it is constructing a proprietary reference standard for population-scale lymphatic health that becomes harder to replicate with each iteration.
01
LymphLens Users
Target: 100,000
02
Anonymized Lymphatic Database
First of its kind globally
03
Clinical Paper #1
Population-level baseline
04
Device Converters
Target: 500–1,000
05
Clinical Paper #2
Intervention efficacy
06
LymphRestore + Patent Platform
Device + Licensing
“No company has ever built a visual, population-scale lymphatic health dataset. Lymphex will own the reference standard.”
05 — Glymphatic Opportunity
The Lymphatic System Is the Billion-Dollar Signal.
The platform’s highest-upside thesis sits at the intersection of cervical lymphatic drainage, glymphatic clearance, and neurodegeneration — where emerging science, federal signaling, and active acquirer behavior are already converging.
What We Know
Research at the University of Rochester identified that the brain clears amyloid-beta and tau protein during sleep via CSF flow through the glymphatic system. This flow is most active during slow-wave sleep in the supine position. Outflow drains through the cervical lymphatic vessels — the same vessels Lymphex targets.
The Hypothesis
Chronic cervical lymphatic stagnation — driven by age-related degradation — may impair glymphatic clearance over decades. This creates a plausible mechanistic link between peripheral lymphatic health and neurodegenerative disease progression. A provisional patent covers this indication.
The Signal
ARPA-H launched the GLIDE program in July 2024 specifically to fund lymphatic repair interventions. The Alzheimer’s therapeutics market is $6.5B today and projected to reach $33.6B by 2034 at 20%+ CAGR. Active acquirers: Biogen, Eli Lilly, Roche, AbbVie, Sanofi.
06 — Competitive Landscape
The Incumbents Own Symptoms. Lymphex Owns the System.
The landscape is populated by large, credible operators, but each one commercializes a narrow endpoint. None has built a lymphatic platform, a consumer wedge, or a data asset that becomes strategically defensive over time.
| Company | Indication | Key Product | TTM Revenue | The Gap |
|---|---|---|---|---|
| Tactile Medical | Lymphedema | Flexitouch Plus | ~$200M | No consumer platform, no data asset |
| Amgen / Horizon | Gout | Krystexxa | ~$600M | Treats uric acid, not lymphatic drainage |
| Pfizer | Erectile Dysfunction | Viagra / sildenafil | ~$1.5B | Vascular dilation only, no lymphatic mechanism |
| Medtronic | Urinary Incontinence | InterStim | ~$800M | Neuromodulation only, no drainage approach |
| Biogen / Eisai | Alzheimer’s | Leqembi | ~$500M | Amyloid drug, no lymphatic pathway |
| No company | Lymphatic Platform | — | $0 | This is Lymphex |
07 — IP Strategy
One Patent. Six Markets. $30 Billion in Indication Revenue.
The provisional patent strategy is designed to establish negotiating leverage across multiple large pharmaceutical and device markets. The objective is not to operationally own every indication; it is to make design-around behavior expensive and strategically unattractive.
Gout
$3.0B
Restless Leg Syndrome
$730M
Erectile Dysfunction
$4.8B
Urinary Incontinence
$8.3B
Alzheimer’s
$6.5B
Peripheral Vascular Disease
$4.0B
Center patent
Lymphex Provisional Patent
Lymphatic Drainage as Intervention Mechanism
“The goal is not to win every indication. The goal is to make every large-cap pharma company in these spaces negotiate rather than design around.”
08 — Indications Expansion Strategy
Six Markets. One Missing Layer. A Disciplined Expansion Sequence.
The expansion strategy is not to assemble unrelated products across six diseases. It is to define the drainage and clearance layer that current high-value markets still measure only indirectly, then allocate capital where the first proof is most evidence-efficient.
| Indication | Burden | Drainage fit | Guideline maturity | Portfolio role |
|---|---|---|---|---|
| Alzheimer’s disease | Very high | Very high | High | Flagship wedge |
| Gout | High | High | High | Peripheral proof point |
| Peripheral artery disease | Very high | Moderate | High | Tissue-recovery adjacency |
| Restless legs syndrome | Moderate | Low / moderate | Moderate | Discovery exploration |
| Erectile dysfunction | High | Low / moderate | High | Segmented extension |
| Urinary incontinence | High | Low | High | Selective extension |
Executive read
Alzheimer’s disease is the flagship wedge. Gout is the clearest peripheral proof point. PAD is the best adjacency. The remaining three markets belong in evidence-led extension tiers rather than first-wave commercialization.
Category thesis
Medicine repeatedly recognizes burden, perfusion loss, or symptoms before it measures the upstream drainage infrastructure itself. Lymphex’s expansion logic is to own that unclaimed operating layer across markets that already accept buildup as clinically real.
Wave 1
Lead wedges
Prioritize the two proof-efficient markets where buildup biology is already accepted and the missing measurement layer is most investable.
Alzheimer’s diseaseGout
Proof threshold
Show clearance-state intelligence alters selection, interpretation, flare risk, or tissue-regression logic.
Wave 2
Adjacency expansion
Expand only after the platform proves transferability into recovery-focused workflows where tissue status remains uneven after standard care.
Peripheral artery diseaseRestless legs syndrome
Proof threshold
Show tissue-status or subgroup signals predict recovery, persistent symptoms, or biologic fragility inside accepted care paths.
Wave 3
Selective extension
Keep capital tight in later-wave categories until Lymphex can isolate narrow subgroups where tissue intelligence changes management.
Erectile dysfunctionUrinary incontinence
Proof threshold
Show a narrow recovery-biology wedge that adds actionable stratification beyond existing phenotype or functional models.
08A — Market-by-Market Detail
Primary Markets, Second-Order Logic, and Third-Order Optionality.
Each indication does not carry equal strategic weight. The markets below are organized to show what standard care already owns, what remains structurally unowned, and where Lymphex can insert a measurable drainage or tissue-intelligence layer with institutional discipline.
Flagship wedge
Alzheimer’s disease
55M+ global dementia burden · 6.9M Americans age 65+ · ¥20.7B Leqembi Q4 FY2025 sales
Timing
Near / mid
Fit
Very high drainage fit
What standard care already solves
Current care already supports biomarker confirmation, staging, selective anti-amyloid therapy, and MRI-monitored safety workflows.
What remains structurally unowned
Routine care still does not quantify glymphatic or meningeal lymphatic dysfunction as a primary clinical variable.
Second-order market logic
This is the cleanest institutional market for Lymphex because clinicians already accept high-complexity, biology-anchored workflows when the rationale is strong.
Third-order platform optionality
The platform opportunity is to become the reference layer between toxic-protein burden and clearance-directed interpretation: who is accumulating, why the brain is failing to clear, and when intervention logic should change.
Required proof threshold
Show clearance-state intelligence can refine selection, longitudinal monitoring, or interpretation inside accepted Alzheimer’s workflows.
Peripheral proof point
Gout
~9–10M U.S. adults · ~4% adult prevalence · $3.0B market today
Timing
Near / mid
Fit
High drainage fit
What standard care already solves
Rheumatology already runs a highly protocolized market built around urate lowering, flare control, prophylaxis, and treat-to-target serum urate titration.
What remains structurally unowned
Standard care cannot routinely explain why tissue crystal burden resolves slowly, unevenly, or incompletely across patients after biochemical control improves.
Second-order market logic
Gout is the most legible bridge from a buildup thesis to a drainage thesis because the pathological material is already clinically accepted and measured as accumulated burden.
Third-order platform optionality
Lymphex can test whether tissue-status intelligence predicts flare recurrence, burden regression, or treatment heterogeneity beyond serum urate alone.
Required proof threshold
Link tissue-status or clearance-linked biology to flare risk, recovery kinetics, or residual disease burden.
Tissue-recovery adjacency
Peripheral artery disease
200M+ global burden · 8–12M U.S. adults · $4.0B indication logic inside patent frame
Timing
Mid
Fit
Moderate drainage fit
What standard care already solves
Vascular care is already rigorous: ABI diagnosis, risk reduction, exercise therapy, wound care, limb surveillance, and revascularization when necessary.
What remains structurally unowned
What remains weakly measured is post-perfusion biology — which limbs stay congested, fragile, non-healing, or biologically unstable after flow improves.
Second-order market logic
PAD should not be framed as a native drainage disease. It is valuable because it exposes a recovery layer that perfusion-centric workflows do not fully explain.
Third-order platform optionality
Lymphex can own the second-order measurement layer around edema resolution, inflammatory persistence, and recovery readiness in high-risk limb care.
Required proof threshold
Show tissue-status signals predict wound healing, persistent symptoms, or biologic fragility after revascularization.
Discovery exploration
Restless legs syndrome
$730M market today · meaningful sleep-neurology burden · fragmented diagnosis and treatment
Timing
Longer
Fit
Low / moderate drainage fit
What standard care already solves
The field is increasingly iron-first and augmentation-aware, with ferritin and transferrin saturation assessment, trigger removal, and alpha-2-delta ligands replacing dopamine-first complacency.
What remains structurally unowned
No specialty workflow currently measures drainage-centered biology, glymphatic status, or lymphatic function in routine RLS care.
Second-order market logic
RLS is strategically interesting because accepted biology already includes iron handling and nocturnal neural physiology, both of which could conceal upstream clearance-linked heterogeneity.
Third-order platform optionality
The credible entry is a subgroup thesis: use tissue-intelligence or clearance signals to discover patients whose iron response, neuroinflammation, or nighttime physiology behaves differently.
Required proof threshold
Identify a reproducible clearance-linked subpopulation rather than making broad category claims.
Segmented extension
Erectile dysfunction
$4.8B market today · durable willingness to pay across drugs, devices, injections, and prosthetics
Timing
Longer
Fit
Low / moderate drainage fit
What standard care already solves
Urology already operates an algorithmic, escalation-based market built around PDE5 inhibitors, devices, injections, prosthesis, and reversible vascular, endocrine, neurologic, or psychogenic contributors.
What remains structurally unowned
Routine pathways rarely quantify tissue recovery quality, interstitial congestion, fibrosis trajectory, or recovery biology behind inconsistent functional response.
Second-order market logic
ED is commercially attractive because the market values measurable function and structured escalation, but the accepted model remains hemodynamic first, not drainage first.
Third-order platform optionality
Lymphex’s wedge would be narrow and data-driven: identify refractory, post-procedural, or recovery-specific subgroups where tissue-status adds predictive power.
Required proof threshold
Show additive stratification or tissue-recovery insight in clearly defined nonresponder or post-intervention cohorts.
Selective extension
Urinary incontinence
$8.3B market today · large chronic burden across urgency and stress phenotypes
Timing
Longer
Fit
Low drainage fit
What standard care already solves
Care is mature and phenotype-specific, spanning behavioral therapy, pelvic-floor training, medications, neuromodulation, botulinum toxin, bulking agents, slings, and surgery.
What remains structurally unowned
Standard algorithms rarely use pelvic tissue edema, inflammatory clearance, or drainage-linked recovery biology as routine decision inputs.
Second-order market logic
UI is operationally large and measurable, but strategically fragmented by phenotype and specialty ownership. That makes broad-category claims weak and narrowly targeted recovery wedges more credible.
Third-order platform optionality
The right entry is a selected tissue-state context — postpartum remodeling, post-procedural healing, chronic inflammation, or pelvic tissue-quality decline — where phenotype labels under-explain outcome variability.
Required proof threshold
Prove a narrow recovery-biology wedge that changes management in a specific subtype or care moment.
08B — Capital Allocation
Advance Markets Only When the Prior Wave Earns the Right to Expand.
The institutional discipline behind the portfolio is capital efficiency rather than thematic enthusiasm. Evidence must travel from biologic signal, to clinical actionability, to specialty-aligned commercialization before Lymphex widens the aperture.
Capital allocation logic
Wave 1
60–70% of effort
Prioritize the two proof-efficient markets where buildup biology is already accepted and the missing measurement layer is most investable.
Wave 2
20–30% of effort
Expand only after the platform proves transferability into recovery-focused workflows where tissue status remains uneven after standard care.
Wave 3
<10% of effort
Keep capital tight in later-wave categories until Lymphex can isolate narrow subgroups where tissue intelligence changes management.
Milestone-based decision rules
Gate 1
A repeatable biologic or tissue-status signal relevant to burden or recovery
Gate 2
Evidence clinicians can act on the signal within accepted workflows
Gate 3
A commercialization path aligned with specialty ownership and reimbursement logic
The exit is not defined by a single product win. It is defined by owning the missing drainage layer across high-value disease markets.
09 — Founder & Structure
Built by Someone Who Has Done It. Three Times.
The founder profile matters because the company is self-funded, structurally unconstrained, and being built around a long-horizon category thesis rather than venture timing requirements.
Founder profile
Jeffrey David Smith
Founder, Lymphex LLC
Self-funded · No external raise planned
Founder, Greenlight Medical → Acquired by Stryker
Founder, Pacific Surgical → Acquired
Founder & CEO, Providence Medical Technology → IPO 2026, ~$1B valuation, ~10.5% founder ownership
Age 47. Self-funded. No venture capital. No board approval required.
“I have had three exits. I am building Lymphex because it is the biggest white space I have ever seen in 25 years of medtech.”
Company structure
Entity
Lymphex LLC
Domicile
Delaware
Structure
Multi-member LLC
Members
Jeffrey David Smith; QSPS Delaware Trust
Investment Advisor
Edward Moss
Capitalization
Fully founder-funded
External raise
None planned
10 — Closing Statement
The Last System. The First Solution.
Every major biological system has a category leader.
Cardiology has its devices. Neurology has its drugs.
The gut has its microbiome companies.
The lymphatic system — which moves more fluid daily than the heart, clears the brain of the proteins that cause Alzheimer’s, and degrades quietly in every person alive over 40 — has no one.
Lymphex is building the reference standard for human lymphatic health. The data platform. The device ecosystem. The patent foundation.
The exit will not be a product sale. It will be a category acquisition.
LX
lymphex
lymphex · lymphex.io · Confidential 2026